Cancer Research UK
Quick facts
Phase 3 pipeline
- releasing hormone agonist therapy · Oncology
Releasing hormone agonist therapy works by mimicking the action of natural hormones to stimulate the release of other hormones.
Phase 2 pipeline
Phase 1 pipeline
- [124I]meta-Iodobenzylguanidine
- ALETA-001
- AST-VAC2
- AT13148
- BI-1206 single agent expansion phase
- BT1718
- DI-B4
- glioblastoma multiforme multipeptide vaccine IMA950
- HMBD-001
- HMBD-001 and enzalutamide
- HTL0039732 Capsules
- HTL0039732 Capsules and atezolizumab infusion
- LY3143921 hydrate
- MOv18 IgE
- multikinase inhibitor AT9283
- Notch signaling pathway inhibitor MK0752
- TT-702
- UCB4594
- Vandetanib, Selumetinib
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Cancer Research UK
What is Cancer Research UK's pipeline?
Cancer Research UK has 1 drugs in Phase 3, 2 in Phase 2, 19 in Phase 1. Late-stage candidates include releasing hormone agonist therapy.
Related
- Sector hub: All tracked pharma companies